Amyloid β-Protein(25-35)

Amyloid β-Protein(25-35), also known as Aβ(25-35) or beta-amyloid fragment 25-35, is a synthetic peptide segment derived from the central region of the full-length amyloid beta protein. This peptide is widely utilized in neuroscience and biochemical research due to its unique propensity to aggregate and its ability to induce cytotoxic effects in neuronal cell cultures. The sequence represents a critical core region believed to contribute significantly to the aggregation and neurotoxic properties observed in amyloid beta pathology. Its solubility, aggregation kinetics, and biological effects closely mimic those of longer amyloid beta species, making it an invaluable tool for modeling amyloid-related phenomena in vitro and in vivo. Researchers benefit from its ease of synthesis and handling compared to longer beta-amyloid variants, while still maintaining the essential biophysical and pathological characteristics necessary for experimental reproducibility and mechanistic studies.

Neurotoxicity Mechanism Studies: Amyloid β-Protein(25-35) is extensively employed in elucidating the molecular mechanisms underlying amyloid-induced neurotoxicity. Scientists utilize this peptide to simulate the pathological conditions associated with amyloid aggregation, particularly in relation to oxidative stress, mitochondrial dysfunction, and apoptotic pathways in neuronal cells. By exposing cultured neurons or brain slices to Aβ(25-35), researchers can observe the cascade of intracellular events leading to cell death, synaptic loss, and impaired neuronal communication. These studies are pivotal in identifying the cellular targets and signaling pathways affected by amyloid toxicity, providing a foundation for the development of neuroprotective strategies and therapeutic interventions in neurodegenerative diseases.

Alzheimer's Disease Research Models: The beta-amyloid fragment 25-35 serves as a robust experimental model for Alzheimer's disease-related studies. Due to its pronounced aggregation properties and ability to induce cognitive deficits in animal models, it is frequently used to replicate key aspects of Alzheimer's pathology, including plaque formation, synaptic dysfunction, and memory impairment. Researchers administer Aβ(25-35) intracerebrally or systemically in rodents to induce behavioral and histopathological changes reminiscent of those observed in Alzheimer's patients. This approach enables the evaluation of potential therapeutic compounds, the investigation of disease-modifying genes, and the assessment of neuroinflammatory responses in a controlled laboratory setting.

Screening of Neuroprotective Agents: Aβ(25-35) is a preferred substrate for screening and characterizing neuroprotective molecules with potential anti-amyloidogenic properties. In vitro assays employing neuronal or glial cultures exposed to this peptide facilitate high-throughput testing of small molecules, peptides, or natural extracts for their ability to prevent aggregation, reduce cytotoxicity, or enhance cell survival. Such screening platforms are instrumental in drug discovery pipelines, allowing for the rapid identification of candidates that may modulate amyloid-induced toxicity and potentially translate into therapeutic leads for neurodegenerative disorders.

Oxidative Stress and Mitochondrial Dysfunction Analysis: The application of the amyloid beta 25-35 fragment extends to the detailed analysis of oxidative stress and mitochondrial impairment in neuronal systems. Researchers exploit its capacity to generate reactive oxygen species and disrupt mitochondrial membrane potential, thereby modeling the oxidative damage observed in neurodegenerative conditions. These studies provide valuable insights into the interplay between amyloid burden, redox imbalance, and energy metabolism, elucidating the cellular vulnerabilities that contribute to progressive neuronal loss and cognitive decline.

Cellular Signaling Pathway Investigation: Utilizing Aβ(25-35), investigators can dissect the alterations in intracellular signaling pathways associated with amyloid exposure. The peptide is often used to probe changes in kinase activity, calcium homeostasis, and transcriptional regulation within neurons and glial cells. By mapping these signaling perturbations, scientists gain a deeper understanding of the molecular events that drive synaptic dysfunction and neuronal degeneration. This knowledge supports the identification of novel molecular targets for intervention and advances the broader comprehension of amyloid-related neurobiology.

In conclusion, Amyloid β-Protein(25-35) remains a cornerstone reagent in neurodegenerative disease research, offering a versatile platform for probing the fundamental processes of amyloid aggregation, neurotoxicity, and cellular signaling disruption. Its utility spans mechanistic studies, disease modeling, drug screening, and the exploration of oxidative and metabolic stress, cementing its role as an indispensable tool for advancing our understanding of amyloid pathophysiology and fostering innovation in the search for effective neuroprotective strategies.

1. High fat diet and GLP-1 drugs induce pancreatic injury in mice

2. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. The effect of B-type allatostatin neuropeptides on crosstalk between the insect immune response and cold tolerance

5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy